RonanRx launches a vertically integrated software stack for personalized GLP-1 and peptide care

What launched

RonanRx, a startup in Y Combinator's S26 batch, has launched on Hacker News with a plan to connect every step between a GLP-1 prescription and the medication arriving at a patient's door. According to the launch post by co-founder Lloyd, the company is building a vertically integrated pharmaceutical operation whose software covers prescribing, telehealth, compounding, manufacturing and delivery, starting with GLP-1 medications and peptides.

The founder argues the industry's problem is structural: telehealth platforms, electronic health records, prescription systems, dispensing software, production and shipping all exist as disconnected pieces, and no single company owns the whole chain. Compounding pharmacies can technically fill customized prescriptions, he writes, but they run on manual, fragmented workflows that are not connected to patient data.

From mask factory to pharmaceuticals

The route into the business is unusual. During the pandemic, Lloyd built one of the largest mask manufacturing facilities in the US, capable of turning raw polypropylene pellets into a million finished masks a day. Drawing on software experience from an earlier YC W10 company, he ran the factory with machine learning and computer vision and vertical integration, growing it to 50 million dollars in revenue before demand faded.

His personal experience with tirzepatide, a GLP-1 medication prescribed after a chicken-only diet plateaued, shaped the product direction. Beyond weight loss, he reports reduced compulsive behavior, and after 18 months on the drug his cardiologist believes open-heart surgery for his congenital aortic stenosis, long predicted for his 40s, could potentially be deferred until his 70s or 80s. He frames pharmaceuticals as the rare domain combining digital, physical, biological and regulatory complexity that a frontier AI model cannot simply replicate.

How the service works

Patients arrive directly or through physician referral. According to the launch post, the company collects medical records, current medications, lab results and wearable data, and its software then follows the prescription through drug formulation, compounding, quality testing, dispensing and distribution.

The company's website describes the care model in more detail. A physician reviews the patient's history and sets the starting dose and titration schedule, and can add a patient-specific adjunct, such as B12 or anti-nausea support, to improve tolerability. A licensed pharmacist then verifies the prescription and releases only what the prescriber ordered. The site stresses that the drug molecule itself stays standard, while the plan around it is tailored. Every preparation is made for one patient, with ingredients traced to specific inventory lots.

The centerpiece is a feedback loop: as treatment progresses, the patient's response becomes data their doctor uses to adjust the plan. Hormone replacement therapy is on a waitlist as a future category, and the founder says the longer-term interest is patient-specific pharmaceutical manufacturing generally.

Pricing claims and open questions

On Hacker News, the founder claims that because the company starts at the molecule and owns the stack from manufacturing through delivery rather than paying middlemen at each step, prices are typically three to ten times more affordable.

The website is more cautious. It says compounded, patient-specific preparations can cost less than cash-pay list prices for brand-name GLP-1s, but a footnote states that RonanRx does not set medication pricing, that actual cost depends on the prescriber's plan, the pharmacy and the state, and that patients may use Elite Care Pharmacy LLC or a pharmacy of their choice. That sits somewhat awkwardly beside the launch post's statement that the company makes money selling drugs it manufactures; the two accounts differ on how much of the chain RonanRx itself operates versus coordinates.

The site also carries regulatory fine print worth noting: compounded medications are not FDA-approved, and availability varies by state and by prescribed medication. The founder closes the post by inviting feedback from anyone who has built pharmacy, manufacturing, clinical or EHR infrastructure, acknowledging that the model rests on assumptions that still need testing.

Why it matters

Telehealth GLP-1 providers have multiplied, but most assemble third-party pieces, a prescribing service here, a compounding pharmacy there, a shipper in between. RonanRx is betting that the fragmentation itself is the opportunity, and that the software-run, vertically integrated manufacturing playbook from the mask business transfers to regulated drugs. If dose personalization is real, fixed-dose GLP-1s are a blunt instrument for patients who respond very differently. The open questions are equally significant: the regulatory standing of compounded GLP-1s, founder-claimed pricing that the company's own website softens, and exactly which parts of the chain RonanRx controls today versus aspires to build.